Immix Biopharma, Inc.IMMXNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank17
Studio
Year-over-Year Change

Cash generated from core business operations

Latest
$-14.38M
↓ 99% vs avg
Percentile
P17
Within normal range
Streak
1 yr
Consecutive growthContracting
Average
$-7.22M
Historical baseline
PeriodValueYoY Change
TTM$-14.38M+1.5%
2024$-14.60M-28.3%
2023$-11.37M-53.5%
2022$-7.41M-366.1%
2021$-1.59M-292.7%
2020$-404694.00+48.8%
2019$-790032.00-